|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01622738 |
|
Date of registration:
|
13/06/2012 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis
|
|
Scientific title:
|
A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis |
|
Date of first enrolment:
|
July 2013 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
http://clinicaltrials.gov/show/NCT01622738 |
|
Study type:
|
Interventional |
|
Study design:
|
Intervention Model: Single Group Assignment, Masking: Open Label
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Howard Trachtman, M.D. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
NYU MEDICAL CENTER |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
Biopsy-proven primary FSGS (Primary FSGS confirmed by renal biopsy report OR documentation
of a genetic mutation in a podocyte protein associated with the disease)
Age minimum:
N/A
Age maximum:
50 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Primary Focal Segmental Glomerulosclerosis
|
|
Intervention(s)
|
|
Drug: RE-021
|
|
Primary Outcome(s)
|
|
Evaluate change in albumin excretion rate (AER) from baseline
|
|
Secondary ID(s)
|
|
RET-D-002
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|